Biotech

All Articles

Gilead spends J&ampJ $320M to go out licensing deal for seladelpar

.With Gilead Sciences about to an FDA decision for its liver condition medication seladelpar, the pr...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks can find the providers setting up tents at basecamp responsible...

Entero giving up personnel, moving out of office and also pausing R&ampD

.Cushion Liquidators has actually switched Entero Therapeutics white as a slab. The financial instit...

Exelixis drops ADC after choosing it is actually no suit for Tivdak

.Exelixis is actually giving up on its cells factor (TF)- targeting antibody-drug conjugate after en...

Relay loses interest in SHP2 prevention after Genentech leaves

.3 weeks after Roche's Genentech unit ignored an SHP2 inhibitor pact, Relay Therapeutics has actuall...

Stoke's Dravet syndrome med released of partial professional grip

.Stoke Rehabs' Dravet syndrome medication has actually been actually without a predisposed grip, get...

Fierce Biotech's Gabrielle Masson offers Tough 15 at NYSE

.Ferocious Biotech Colleague Editor Gabrielle Masson offered the 2024 class of Fierce 15 champions o...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH prospect

.Novo Nordisk has axed its own once-monthly double GLP-1/ GIP receptor agonist, finishing (PDF) adva...

Daiichi pays Merck $170M to form bronchi cancer T-cell engager contract

.Merck &amp Co. has actually rapidly redeemed a few of the prices of its Harpoon Rehabs purchase, at...

BioMarin stops preclinical gene therapy for heart disease

.After BioMarin performed a spring season tidy of its own pipeline in April, the provider has made a...